Hepatocarcinoma Clinical Trial
— PERSEEOfficial title:
Essai Clinique Pour Une Endomicroscopie Robotisée Dans la redéfinition Des Stratégies d'ExérèsE (PERSÉE) appliquée à la Chirurgie Hépatique
Verified date | January 2019 |
Source | Mauna Kea Technologies |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study aims at assessing the feasibility of Probe-based Confocal Laser Endomicroscopy (pCLE) during laparoscopic hepatic masses resection for intra-operative characterisation of hepatic masses and surgical margins assessment.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | January 7, 2020 |
Est. primary completion date | January 7, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Over 18 years - Scheduled for a surgical resection of hepatic masses - Provided signed informed consent Exclusion Criteria: - Allergy to Indocyanine green (ICG) - Kidney failure - Pregnancy or breastfeeding |
Country | Name | City | State |
---|---|---|---|
France | Institut Mutualiste Montsouris | Paris |
Lead Sponsor | Collaborator |
---|---|
Mauna Kea Technologies |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | malignant pCLE criteria | Definition of pCLE criteria for normal and malignant hepatic tissues | 1 year | |
Secondary | pathological pCLE criteria | Definition of pCLE criteria for pathological hepatic parenchyma (non tumoral) | 1 year | |
Secondary | Ease of use of the endomicroscopy device | The ease of use of the endomicroscopy device will be assessed using a questionnaire that the surgeon will fill at the end of each procedure | 1 year | |
Secondary | Audio/video telecommunication quality | The telecommunication quality will be assessed using a questionnaire that the surgeon and the anatomopathologist will fill at the end of each procedure | 1 year | |
Secondary | Number of participants with CLE imaging-related adverse events as assessed by CTCAE v5.0 | The device safety will be measured by assessing the occurence and severity of adverse events during the study | 1 year | |
Secondary | Stability and reproducibility of images/sequences during procedures | The stability and reproducibility of endomicroscopy images will be assessed using a questionnaire that the surgeon and the anatomopathologist will fill at the end of each procedure | 1 year | |
Secondary | pCLE criteria diagnostic performance | The diagnostic performance of identified pCLE criteria will be expressed by their sensitivities, specificities, negative predictive value and positive predictive value. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06041490 -
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
|
Phase 2 | |
Terminated |
NCT03956940 -
Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib
|
N/A | |
Completed |
NCT03382327 -
Benefit of the Use of 3D Models and Tools in Hepatectomy Planning for Hepatocarcinomas
|
N/A | |
Recruiting |
NCT03755739 -
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
|
Phase 2/Phase 3 | |
Recruiting |
NCT06028724 -
A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
|
||
Recruiting |
NCT05794048 -
METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors
|
N/A | |
Recruiting |
NCT04435977 -
Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma
|
Phase 2 | |
Completed |
NCT04811898 -
A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment
|
Phase 1 | |
Recruiting |
NCT05311319 -
HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection
|
Phase 2 | |
Completed |
NCT05464706 -
Study on the Quality of Life (QoL) After Liver Surgery
|
N/A | |
Completed |
NCT01411579 -
Use of DwI-MR to Predict Chemotherapy Response of Liver Metastases and Hepatocarcinoma
|
N/A | |
Completed |
NCT02519075 -
11C-Choline PET/CT and DWI MRI for Response Assessment of HCC Candidate to TARE
|
||
Recruiting |
NCT03356236 -
Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation
|